Key result
Heparin is linked to ~25% lower mortality vs bishydroxycoumarin, with fewer thrombotic but more embolic events.
Why the study?
Does heparin compared to bishydroxycoumarin affect the rates of thrombotic complications, embolic complications, and death in patients requiring anticoagulation?
Observational (n=164)
Does heparin compared to bishydroxycoumarin affect the rates of thrombotic complications, embolic complications, and death in patients requiring anticoagulation?
Absolute Event Rate: 28% vs 37.5%
Heparin and bishydroxycoumarin exhibit different profiles of thrombotic and embolic complications, with mortality outcomes heavily dependent on the adequacy of the anticoagulant therapy.
Trade-offs in thrombotic versus embolic risks may guide anticoagulant selection; leaves open optimal choice pending randomized data.
Thrombotic complications dominated in the group treated with bishydroxycoumarin (12, compared to 5 in the heparin group). Embolic complications predominated in those treated with heparin (five, compared to one in the bishydroxycoumarin group). Of 52 patients receiving adequate bishydroxycoumarin therapy, 16 died; 8 in the group of 12 died while receiving inadequate therapy. Of 75 with adequate heparinization, 16 died; 12 out of 25 died with inadequate heparin therapy. Three or more complications were followed by death in 11 of 19 given bishydroxycoumarin and 14 of 60 given heparin.
No takes yet. Share an insight, caveat, or question.
George C. Griffith (1960) conducted an observational in Patients requiring anticoagulant therapy (n=164). Heparin vs. Bishydroxycoumarin was evaluated on Mortality. Heparin therapy was associated with fewer thrombotic complications but more embolic complications compared to bishydroxycoumarin, with an overall mortality rate of 28% versus 37.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: